|dc.description.abstract||Drug resistance is a major concern in the treatment of numerous diseases caused by infectious agents, creating an urgent need for new treatments. In this study, I assessed the effectiveness of compounds against two medically important lung pathogens, Mycobacterium tuberculosis and Pseudomonas aeruginosa, using complementary methods of drug discovery and assessment.
The first approach identified high-affinity iron chelators of the pyridoxal isonicotinoyl hydrazone (PIH) class that could restrict the growth of clinically significant mycobacteria, using both in vitro and in vivo infection models. In a second study, novel chemical scaffolds, termed metal-cyclam complexes (MCyC), were found to be specifically active against pathogenic mycobacteria, displayed relatively low toxicity and in some cases displayed a synergistic effect with currently used treatments. The final study used high-throughput screening assays to identify a small subset of compounds that could inhibit the growth of Pseudomonas and mycobacterial species, from a library of 1920 compounds made up of a diverse series of natural and synthetic products.
In conclusion, this thesis has identified lead products that with additional study/modification could lead to viable compounds for future treatment of pathogenic bacterial infection in humans.||en_AU|
|dc.publisher||University of Sydney.||en_AU|
|dc.publisher||Infectious Diseases and Immunology.||-|
|dc.publisher||Central Clinical School - RPAH.||-|
|dc.title||Identification and characterisation of new compounds to treat chronic bacterial lung infections||en_AU|
|dc.type.pubtype||Doctor of Philosophy Ph.D.||en_AU|
|Appears in Collections:||Sydney Digital Theses (Open Access)|